PPARA and metabolic syndrome: Currently, fibrates (synthetic PPARα agonists) are used to treat dyslipidemia, whereas the class of antidiabetic Thiazolidinediones (TZDs) targeting PPARγ had been widely prescribed for the management of T2D but are now partially withdrawn from clinical use due to their side effects [3,4,5].